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Background: The optimal extent of groin completion lymph node dissection (CLND) (inguinal or
ilioinguinal dissection) in patients with melanoma is controversial. The aim of this study was to evaluate
whether the extent of groin CLND after a positive sentinel node biopsy (SNB) is associated with improved
outcome.
Methods: Data from all sentinel node-positive patients who underwent groin CLND at four tertiary
melanoma referral centres were retrieved retrospectively. Baseline patient and tumour characteristics
were collected for descriptive statistics, survival analyses and Cox proportional hazards regression
analyses.
Results: In total, 255 patients were included, of whom 137 (53⋅7 per cent) underwent inguinal dissection
and 118 (46⋅3 per cent) ilioinguinal dissection. The overall CLND positivity rate was 18⋅8 per cent; the
inguinal positivity rate was 15⋅5 per cent and the pelvic positivity rate was 9⋅3 per cent. The pattern
of recurrence, and 5-year melanoma-specific survival, disease-free survival and distant-metastasis free
survival rates were similar for both dissection types, even for patients with a positive CLND result. Cox
regression analysis showed that type of CLNDwas not associated with disease-free or melanoma-specific
survival.
Conclusion: There was no significant difference in recurrence pattern and survival rates between patients
undergoing inguinal or ilioinguinal dissection after a positive SNB, even after stratification for a positive
CLND result. An inguinal dissection is a safe first approach as CLND in patients with a positive SNB.
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Introduction
Although evidence for a therapeutic benefit is still lacking
pending the final results of Multicentre Selective Lympha-
denectomy Trial (MSLT) II, many current melanoma
guidelines advise consideration of completion lympha-
denectomy (CLND) in case of a positive sentinel node
biopsy (SNB)1–4. This is in line with the opinion of 91⋅8
per cent of 193melanoma surgeons worldwide, but in prac-
tice only half of patients with a positive sentinel node (SN)
actually undergo CLND5,6. In the groin area, CLND can
be classified as an inguinal dissection with removal of all
femoral and inguinal lymph nodes, or an ilioinguinal dis-
section with additional removal of all iliac (up to the bifur-
cation of the common iliac artery) and obturator lymph
nodes.
The optimal surgical extent of CLND in the groin is
controversial. Some authors7–9 advocate ilioinguinal dis-
section to optimize regional control and possibly increase
survival. Others10–16 disagree and advocate an inguinal dis-
section, especially in patients with low suspicion of pelvic
nodal metastasis, because ilioinguinal dissection is believed
to be associated with increased morbidity and does not
seem to affect outcome.
Few studies have compared the therapeutic benefit of
inguinal and ilioinguinal dissection solely in patients with
melanoma and a positive SNB. The majority of stud-
ies comparing these two types of dissection have been
limited to those with palpable disease7,11,15, or did not
differentiate between patients with a positive SNB or pal-
pable disease8,17. It has been demonstrated, however, that
© 2017 The Authors. BJS published by John Wiley & Sons Ltd on behalf of BJS Society Ltd. BJS
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
D. Verver, M. F. Madu, C. M. C. Oude Ophuis, M. Faut, J. H. W. de Wilt, J. J. Bonenkamp et al.
Inguinal dissection
Anterior superior iliac spine
External iliac nodes
Inguinal ligament
Superficial inguinal nodes
Superficial femoral nodes
Femoral artery
and vein
Aorta
Inferior vena cava
Internal iliac nodes
Obturator nodes
Deep femoral nodes
Long saphenous vein
Ilioinguinal dissection
Fig. 1 Nodes removed in inguinal versus ilioinguinal completion lymph node dissection in the groin
patients with a positive SNBdiffer from those with palpable
disease in tumour biology, rate of pelvic nodal involvement,
recurrence pattern and survival rate8,13,14,17–19.
The aim of the present study was to evaluate whether
the extent of groin CLND in patients with a positive SNB
was associated with better outcome. For this purpose, data
from four tertiary large melanoma centres in the Nether-
lands were retrieved. Recurrence patterns, disease-free sur-
vival (DFS), distant metastasis-free survival (DMFS) and
melanoma-specific survival (MSS) were compared after
inguinal and ilioinguinal dissection.
Methods
Patients with a positive SNB and subsequent CLND in the
groin were identified from retrospective SNB melanoma
databases in four tertiary melanoma centres in the Nether-
lands, two of which routinely performed inguinal dissection
and two ilioinguinal dissection. Patient characteristics (age,
sex), tumour characteristics (histology, Breslow thickness),
SN characteristics (tumour burden), CLND outcomes and
follow-up data were extracted from the databases of the
participating centres.
Sentinel node biopsy
SNB was performed for primary melanomas at least
1⋅00mm thick, or shallower than 1⋅00mm but with
ulceration or other adverse tumour characteristics (Clark
level IV–V or at least 1 mitosis/mm2 depending on the
AJCC staging edition at the time of diagnosis). The triple
technique was used, as described previously20–22.
Completion lymphadenectomy
In general, theDutchMelanomaGuidelines2 were adhered
to by all participating centres for preoperative and post-
operative management; preoperative or postoperative
imaging was not indicated.
The local policy of centres 1 and 4 was inguinal dissection
with removal of inguinal nodes only as standard treatment,
whereas in centres 2 and 3 the routine practice was ilio-
inguinal dissection with additional removal of all iliac and
obturator nodes (Fig. 1). Sometimes surgeons deviated
from this routine practice, based on factors such as age,
co-morbidities, drainage patterns during lymphoscinti-
graphy and number of positive SNs. Unfortunately,
these reasons are heterogeneous and not amenable to
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Table 1 Patient and tumour characteristics for all patients and those with a positive completion lymph node dissection result
All patients Positive CLND result
Inguinal
dissection (n=137)
Ilioinguinal
dissection (n=118) P†
Inguinal
dissection (n=15)
Ilioinguinal
dissection (n=33) P†
Baseline data
Treatment centre <0⋅001 < 0⋅001§
1 67 (48⋅9) 5 (4⋅2) 8 (53) 2 (6)
2 34 (24⋅8) 44 (37⋅3) 4 (27) 8 (24)
3 17 (12⋅4) 63 (53⋅4) 1 (7) 22 (67)
4 19 (13⋅9) 6 (5⋅1) 2 (13) 1 (3)
Age (years)* 52 (39–62) 50 (38–63) 0⋅915‡ 52 (40–56) 57 (44–65) 0⋅201‡
Sex (F :M) 78 : 59 52 : 66 0⋅040 11 : 4 8 : 25 0⋅001
Primary site 0⋅358 0⋅307
Leg 105 (76⋅6) 96 (81⋅4) 12 (80) 31 (94)
Trunk 32 (23⋅4) 22 (18⋅6) 3 (20) 2 (6)
Histological type 0⋅098 0⋅828§
SSM 69 (50⋅4) 62 (52⋅5) 10 (67) 16 (48)
NM 36 (26⋅3) 35 (29⋅7) 4 (27) 10 (30)
ALM 10 (7⋅3) 10 (8⋅5) 1 (7) 4 (12)
Other 2 (1⋅5) 5 (4⋅2) 0 (0) 2 (6)
Unknown 20 (14⋅6) 6 (5⋅1) 0 (0) 1 (3)
Breslow thickness (mm)* 2⋅90 (1⋅74–4⋅50) 2⋅80 (1⋅80–4⋅70) 0⋅720‡ 2⋅70 (2⋅00–5⋅50) 3⋅50 (2⋅40–5⋅20) 0⋅367‡
pT category (mm) 0⋅656§ 0⋅465§
pT1 (<1⋅00) 1 (0⋅7) 4 (3⋅4) 0 (0) 1 (3)
pT2 (1⋅01–2⋅00) 38 (27⋅7) 31 (26⋅3) 4 (27) 3 (9)
pT3 (2⋅01–4⋅00) 60 (43⋅8) 48 (40⋅7) 6 (40) 16 (48)
pT4 (> 4⋅00) 37 (27⋅0) 34 (28⋅8) 5 (33) 13 (39)
Unknown 1 (0⋅7) 1 (0⋅8) 0 (0) 0 (0)
Ulceration 0⋅003 0⋅158§
No 60 (43⋅8) 64 (54⋅2) 6 (40) 15 (45)
Yes 57 (41⋅6) 51 (43⋅2) 6 (40) 17 (52)
Unknown 20 (14⋅6) 3 (2⋅5) 3 (20) 1 (3)
SN analysis
No. of SNs* 2 (1–2) 2 (1–3) 0⋅226‡ 1 (1–2) 2 (1–3) 0⋅057‡
No. of non-SNs* 0 (0–0) 0 (0–0) 0⋅144‡ 0 (0–0) 0 (0–0) 0⋅176‡
No. of positive SNs* 1 (1–1) 1 (1–2) 0⋅225‡ 1 (1–1) 1 (1–2) 0⋅025‡
No. of positive non-SNs 0 (0) 0 (0) 1⋅000 0 (0) 0 (0) 1⋅000
SN tumour burden (mm) 0⋅003 0⋅164
<0⋅1 16 (11⋅7) 4 (3⋅4) 0 (0) 0 (0)
0⋅1–1⋅0 52 (38⋅0) 45 (38⋅1) 4 (27) 12 (36)
>1⋅0 30 (21⋅9) 46 (39⋅0) 5 (33) 16 (48)
Unknown 39 (28⋅5) 23 (19⋅5) 6 (40) 5 (15)
Values in parentheses are percentages unless indicated otherwise; *values are median (i.q.r.). CLND, completion lymph node dissection; SSM, superficial
spreading melanoma; NM, nodular melanoma; ALM, acral lentiginous melanoma; SN, sentinel node. †χ2 test, except ‡Mann–Whitney U test and
§Fisher’s exact test.
retrospective analysis. Ilioinguinal dissection was per-
formed either via a single inguinal elliptical incision
extending cranially, or via two separate transverse incisions,
as described previously15,23.
Pathology
SNs were processed according to the European Organisa-
tion for Research and Treatment of Cancer (EORTC) SN
pathology protocol24. CLND specimens were processed in
a standard fashion; all lymph nodes were bisected or tri-
sected, and stained with haematoxylin and eosin. Pathology
reports were considered adequate when the total number
of removed and involved lymph nodes was mentioned. For
ilioinguinal specimens, the number of both inguinal and
pelvic nodes removed, and number of positive nodes were
also recorded, if available.
Statistical analysis
Differences between the two treatment groups were calcu-
lated using χ2 tests, Fisher’s exact tests or non-parametric
Mann–Whitney U tests, as appropriate. Where data
were missing or unknown, an ‘unknown’ subcategory was
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Table 2 Outcomes for all patients and those with a positive completion lymph node dissection result
All patients Positive CLND result
Inguinal
dissection (n=137)
Ilioinguinal
dissection (n=118) P‡
Inguinal
dissection (n=15)
Ilioinguinal
dissection (n=33) P‡
CLND result
No. of LNs* 8 (5–11) 14 (10–20) <0⋅001§ 7 (4–11) 15 (10–23) < 0⋅001§
No. of positive LNs* 0 (0–0) 0 (0–1) <0⋅001§ 1 (1–2) 2 (1–4) 0⋅125§
No. of LNs including SNBtot* 10 (7–13) 16 (12–22) <0⋅001§ 9 (5–12) 18 (13–25) <0⋅001§
No. of positive LNs including SNBtot* 1 (1–2) 1 (1–3) 0⋅007§ 2 (2–3) 3 (3–6) 0⋅009§
No. of inguinal LNs* 8 (5–10) (n=135) 8 (5–11) (n=96) 0⋅417§ 7 (4–11) 9 (7–16) (n=29) 0⋅062§
No. of positive inguinal LNs* 0 (0–0) (n=135) 0 (0–0) (n=114) 0⋅014§ 1 (1–2) 1 (1–3) (n=29) 0⋅842§
No. of pelvic LNs* – 5 (3–9) (n=96) – – 5 (2–9) (n=29) –
No. of positive pelvic LNs* – 0 (0–0) (n=114) – – 0 (0–1) (n=29) –
Positive LNs 0⋅018¶ 0⋅018¶
Inguinal only 15 (100) 18 (55) 15 (100) 18 (55)
Pelvic only 0 (0) 4 (12) 0 (0) 4 (12)
Inguinal and pelvic 0 (0) 7 (21) 0 (0) 7 (21)
Unknown 0 (0) 4 (12) 0 (0) 4 (12)
Follow-up
Adjuvant immunotherapy† 0⋅024 0⋅004¶
No 7 (5⋅1) 3 (2⋅5) 5 (33) 1 (3)
Yes 16 (11⋅7) 4 (3⋅4) 1 (7) 1 (3)
Unknown 114 (83⋅2) 111 (94⋅1) 9 (60) 31 (94)
Adjuvant radiotherapy <0⋅001 0⋅001¶
No 36 (26⋅3) 98 (83⋅1) 4 (27) 23 (70)
Yes 4 (2⋅9) 6 (5⋅1) 1 (7) 6 (18)
Unknown 97 (70⋅8) 14 (11⋅9) 10 (67) 4 (12)
Recurrence 0⋅786 0⋅287
No 72 (52⋅6) 60 (50⋅8) 2 (13) 9 (27)
Yes 65 (47⋅4) 58 (49⋅2) 13 (87) 24 (73)
Site of first recurrence 0⋅394 0⋅125¶
Locoregional 31 (48) 34 (59) 2 (15) 9 (38)
Regional LNs 8 (12) 4 (7) 0 (0) 3 (13)
Distant 26 (40) 20 (34) 11 (85) 12 (50)
Any regional LN recurrence 0⋅132 1⋅000
No 120 (87⋅6) 110 (93⋅2) 13 (87) 28 (85)
Yes 17 (12⋅4) 8 (6⋅8) 2 (13) 5 (15)
Site of regional recurrence 0⋅181¶ 0⋅095¶
Inguinal only 5 (29) 1 (13) 1 (50) 0 (0)
Inguinal and pelvic 6 (35) 1 (13) 1 (50) 0 (0)
Pelvic only 5 (29) 4 (50) 0 (0) 3 (60)
Popliteal 1 (6) 0 (0) 0 (0) 0 (0)
Unknown 0 (0) 2 (25) 0 (0) 2 (40)
Values in parentheses are percentages unless indicated otherwise; *values are median (i.q.r.). †Interferon-α or dendritic cell therapy. CLND, completion
lymph node dissection; LN, lymph node; SNBtot, number of sentinel nodes plus non-sentinel nodes during sentinel node biopsy. ‡χ2 test, except
§Mann–Whitney U test and ¶Fisher’s exact test.
created and included in the analysis. MSS was calculated
from the date of CLND until last follow-up or death
from melanoma; deaths from other causes were censored.
DFS was calculated from the date of CLND to the date
of first recurrence or the date of last-follow-up or death.
DMFS was calculated from the date of CLND to the
date of first distant metastasis or date of last follow-up
or death. The Kaplan–Meier method was used to esti-
mate survival, and differences between groups were
assessed by means of the log rank test. Multivariable Cox
proportional hazards regression analyses were performed
to identify prognostic co-variables. Two-sided P< 0⋅050
was considered statistically significant. SPSS® version
22.0 was used for all statistical analyses (IBM, Armonk,
New York, USA).
Results
A total of 283 patients treated between 1994 and 2014 were
identified from the SNB databases. Twenty-eight patients
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Fig. 2 Five-year a melanoma-specific survival, b disease-free survival and c distant metastasis-free survival after inguinal and ilioinguinal
completion lymph node dissection (CLND). a P= 0⋅184, b P= 0⋅169, c P= 0⋅143 (log rank test)
were excluded for the following reasons: palpable disease
or distant metastases before surgery (9); missing data on
CLND date and resected specimen (7); additional positive
SNB outside the groin (9); no available follow-up (2); and
altered choice of surgery owing to pregnancy (1). The
remaining 255 patients were analysed. Median follow-up
for all patients was 51 (i.q.r. 26–99) months. Baseline
patient and tumour characteristics are shown in Table 1. An
inguinal dissection was performed in 137 patients (53⋅7 per
cent) and an ilioinguinal dissection in 118 (46⋅3 per cent).
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The ilioinguinal group included more men (P= 0⋅040)
and had a significantly higher SN tumour burden
(P= 0⋅003).
Forty-eight patients (18⋅8 per cent) had additional lymph
node metastases in the CLND specimen (positive CLND),
15 in the inguinal dissection group and 33 in the ilio-
inguinal dissection group. The overall inguinal positivity
rate (with or without additional pelvic positivity) was 15⋅7
per cent (40 of 255), and the overall pelvic positivity rate
(with or without additional inguinal positivity) was 9⋅3 per
cent (11 of 118).
The median number of inguinal lymph nodes removed
was similar for both dissection types (P= 0⋅417), but the
median number of positive inguinal lymph nodes was sig-
nificantly greater for patients undergoing ilioinguinal dis-
section (P= 0⋅014) (Table 2). In patients with a positive
CLND, the median numbers of both removed and posi-
tive inguinal lymph nodes were similar for both dissection
types (P= 0⋅062 and P= 0⋅842 respectively).
Twenty patients participated in an adjuvant immunother-
apy trial, ten in an EORTC interferon-α trial25 and ten in a
dendritic cell therapy trial26. Another ten patients received
adjuvant radiotherapy.
Recurrence
The overall recurrence rate was 47⋅4 per cent (65 of 137)
after inguinal dissection and 49⋅2 per cent (58 of 118)
after ilioinguinal dissection (P= 0⋅786). For both dissection
types, most patients presented with locoregional recur-
rence only (such as in-transit metastasis) or distant recur-
rence (distant subcutaneous, distant lymph nodes or dis-
tant visceral) at first presentation of relapse. First relapse
in the regional lymph node basin (similar to the CLND
basin) occurred less often, in 12 per cent (8 of 65) after
inguinal dissection and 7 per cent (4 of 58) after ilioinguinal
dissection (P= 0⋅394). During follow-up, another nine
patients in the inguinal dissection group and five in the ilio-
inguinal dissection group presented with a second relapse
located in the regional lymph node basin. Thus, the over-
all regional lymph node recurrence rate was 12⋅4 per cent
(17 of 137) after inguinal dissection and 6⋅8 per cent (8 of
118) after ilioinguinal dissection (P= 0⋅132). The specified
locations of regional lymph node recurrences are shown in
Table 2.
The overall recurrence rate for patients with a positive
CLND result was 87 per cent (13 of 15) after inguinal
dissection and 73 per cent (24 of 33) after ilioinguinal
dissection (P= 0⋅287). The overall regional lymph node
recurrence rate was 13 per cent (2 of 15) and 15 per cent (5
of 33) respectively (P= 1⋅000) (Table 2).
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Fig. 3 Five-year melanoma-specific survival for patients with a
positive or negative result of inguinal or ilioinguinal completion
lymph node dissection (CLND). P= 0⋅767, inguinal positive
versus ilioinguinal positive (log rank test)
Survival
Five-year estimatedMSS, DFS andDMFS rates were 73⋅2,
59⋅2 and 70⋅4 per cent respectively after inguinal dissec-
tion, and 66⋅4, 53⋅1 and 62⋅5 per cent after ilioinguinal
dissection (P= 0⋅184, P= 0⋅169 and P= 0⋅143 respectively)
(Fig. 2).
For patients with a positive CLND, the 5-year estimated
MSS, DFS and DMFS rates were 40, 26 and 26 per cent
respectively after inguinal dissection, compared with 46,
30 and 36 per cent after ilioinguinal dissection (P= 0⋅767,
P= 0⋅978 and P= 0⋅651 respectively). Results for MSS are
illustrated in Fig. 3.
Univariable Cox proportional hazards regression analy-
ses for DFS and MSS included all baseline and treatment
characteristics. In multivariable analysis for DFS, advanced
age, unknown histology, higher SN tumour burden and
a positive CLND result were adverse prognostic factors
(Table 3). In multivariable analysis for MSS, only advanced
age and positive CLND were adverse prognostic factors
(Table 4).
In univariable analysis of prognostic factors in the sub-
group of 48 patients with a positive CLND, type of dissec-
tion was not a significant prognostic factor for DFS (hazard
ratio (HR) (ilioinguinal versus inguinal dissection) 0⋅88, 95
per cent c.i. 0⋅44 to 1⋅76; P= 0⋅713) or for MSS (HR 0⋅82,
0⋅38 to 1⋅79; P= 0⋅622).
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Table 3 Cox proportional hazards regression model for disease-free survival
Univariable analysis Multivariable analysis
Variable n Hazard ratio P Hazard ratio P
Age 255 1⋅02 (1⋅01, 1⋅04) <0⋅001 1⋅02 (1⋅01, 1⋅03) 0⋅002
Breslow thickness 253 1⋅10 (1⋅04, 1⋅15) 0⋅001 1⋅03 (0⋅96, 1⋅11) 0⋅377
Ulceration
No 124 1⋅00 (reference) 1⋅00 (reference)
Yes 108 1⋅70 (1⋅17, 2⋅48) 0⋅005 1⋅36 (0⋅90, 2⋅04) 0⋅143
Unknown 23 1⋅15 (0⋅60, 2⋅21) 0⋅671 0⋅61 (0⋅29, 1⋅28) 0⋅192
Histology
SSM 131 1⋅00 (reference) 1⋅00 (reference)
NM 71 1⋅66 (1⋅09, 2⋅52) 0⋅017 1⋅39 (0⋅89, 2⋅18) 0⋅148
ALM 20 2⋅04 (1⋅09, 3⋅83) 0⋅027 1⋅80 (0⋅91, 3⋅53) 0⋅090
Other 7 1⋅25 (0⋅39, 4⋅02) 0⋅704 0⋅65 (0⋅19, 2⋅22) 0⋅495
Unknown 26 1⋅91 (1⋅09, 3⋅36) 0⋅024 1⋅94 (1⋅01, 3⋅75) 0⋅048
SN tumour burden (mm)
<0⋅1 20 1⋅00 (reference) 1⋅00 (reference)
0⋅1–1⋅0 97 6⋅12 (1⋅48, 25⋅30) 0⋅012 4⋅42 (1⋅05, 18⋅58) 0⋅042
>1⋅0 76 10⋅33 (2⋅49, 42⋅86) 0⋅001 6⋅78 (1⋅60, 28⋅78) 0⋅009
Unknown 62 7⋅87 (1⋅90, 32⋅65) 0⋅004 6⋅12 (1⋅46, 25⋅73) 0⋅013
CLND type
Inguinal 137 1⋅00 (reference) 1⋅00 (reference)
Ilioinguinal 118 1⋅14 (0⋅80, 1⋅63) 0⋅464 0⋅80 (0⋅54, 1⋅19) 0⋅271
CLND result
Negative 207 1⋅00 (reference) 1⋅00 (reference)
Positive 48 2⋅83 (1⋅92, 4⋅17) <0⋅001 2⋅82 (1⋅84, 4⋅33) <0⋅001
Values in parentheses are 95 per cent confidence intervals. SSM, superficial spreading melanoma; NM, nodular melanoma; ALM, acral lentiginous
melanoma; SN, sentinel node; CLND, completion lymph node dissection. The multivariable analysis was adjusted for age (continuous), Breslow thickness
(continuous), ulceration, Rotterdam criteria, CLND type and CLND result. Not shown (not significant in univariable analysis): treatment centre, sex,
location, total number of SNs, number of positive SNs and SN ratio. The categories adjuvant immunotherapy and radiotherapy were not included in the
multivariable analysis; both were significant in univariable analysis, but this was no longer the case when the analysis was corrected for CLND result.
Table 4 Cox proportional hazards regression model for melanoma-specific survival
Univariable analysis Multivariable analysis
Variable n Hazard ratio P Hazard ratio P
Age 255 1⋅02 (1⋅00, 1⋅03) 0⋅015 1⋅02 (1⋅00, 1⋅03) 0⋅023
Breslow thickness 253 1⋅09 (1⋅02, 1⋅16) 0⋅012 1⋅03 (0⋅95, 1⋅12) 0⋅538
Ulceration
No 124 1⋅00 (reference) 1⋅00 (reference)
Yes 108 1⋅64 (1⋅05, 2⋅56) 0⋅031 1⋅38 (0⋅84, 2⋅26) 0⋅206
Unknown 23 1⋅18 (0⋅55, 2⋅54) 0⋅637 0⋅90 (0⋅41, 2⋅00) 0⋅795
SN tumour burden (mm)
<0⋅1 20 1⋅00 (reference) 1⋅00 (reference)
0⋅1–1⋅0 97 1⋅99 (0⋅60, 6⋅67) 0⋅260 1⋅37 (0⋅40, 4⋅64) 0⋅618
>1⋅0 76 4⋅93 (1⋅51, 16⋅16) 0⋅008 2⋅82 (0⋅83, 9⋅59) 0⋅097
Unknown 62 3⋅22 (0⋅98, 10⋅65) 0⋅055 2⋅51 (0⋅75, 8⋅48) 0⋅137
CLND type
Inguinal 137 1⋅00 (reference) 1⋅00 (reference)
Ilioinguinal 118 1⋅24 (0⋅81, 1⋅90) 0⋅319 0⋅91 (0⋅57, 1⋅46) 0⋅704
CLND result
Negative 207 1⋅00 (reference) 1⋅00 (reference)
Positive 48 3⋅12 (1⋅99, 4⋅90) <0⋅001 2⋅97 (1⋅82, 4⋅83) <0⋅001
Values in parentheses are 95 per cent confidence intervals. SN, sentinel node; CLND, completion lymph node dissection. The multivariable analysis was
adjusted for age (continuous), Breslow thickness (continuous), ulceration, Rotterdam criteria, CLND type and CLND result. Not shown (not significant
in univariable analysis): treatment centre, sex, location, histology, total number of SNs, number of positive SNs, SN ratio and adjuvant immunotherapy
(interferon-α or dendritic cell therapy). The category adjuvant radiotherapy was not included in the multivariable analysis; it was significant in univariable
analysis but this was no longer the case when the analysis was corrected for CLND result.
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Discussion
The extent of groin CLND (inguinal or ilioinguinal dissec-
tion) did not affect recurrence patterns and survival rates
in patients with melanoma and a positive SNB. Even when
stratified for a positive CLND result, outcomes were not
significantly different.
The overall CLND positivity rate was 18⋅8 per cent; the
inguinal positivity rate was 15⋅7 per cent (including patients
with additional positive pelvic nodes) and the pelvic posi-
tivity rate 9⋅3 per cent (including patients with additional
positive inguinal nodes). Similar rates have been reported
previously27–29. The inguinal positivity rate after ilio-
inguinal dissection was significantly higher than that after
inguinal dissection, presumably as a result of unfavourable
preoperative characteristics (such as higher SN tumour
burden) as the median number of removed inguinal nodes
was similar for both dissection types.
Both in the overall cohort and in the subgroup of patients
with a positive CLND result there were no significant
differences in recurrence patterns between dissection types,
including regional lymph node recurrence. These results
indicate that the extent of surgery was not associated with
recurrence, even though the pelvic nodes remained in situ
after inguinal dissection, with the theoretical possibility of
microscopic disease being present already. It also seems
that ilioinguinal dissection was not associated with superior
regional disease control. A previous smaller study19 of 94
patients reported a regional lymph node recurrence rate of
12 per cent after inguinal dissection compared with 17 per
cent after ilioinguinal dissection (P= 0⋅66).
Estimated 5-year MSS, DFS and DMFS rates did not
differ significantly between patients undergoing inguinal
or ilioinguinal dissection, both in the overall cohort and
in the CLND-positive subgroup. Moreover, Cox regres-
sion showed that dissection type was not associated with
DFS and MSS. These results indicate that a more radi-
cal dissection in the groin area in patients with a positive
SNB is not associated with superior survival rates. Previ-
ous small studies reported an overall survival rate of 72
per cent after inguinal dissection compared with 69 per
cent after ilioinguinal dissection (P= 0⋅38), and 76 versus
80 per cent respectively (P= 0⋅80)29. In another small
study30, there was no significant difference in estimated
5-year overall survival (P= 0⋅604). Previously reported
DFS rates were 54 per cent after inguinal dissection and 61
per cent after ilioinguinal dissection (P= 0⋅69)29. Another
study19 reported no significant differences in pelvic node
recurrence-free survival (P= 0⋅80) and DFS (P= 0⋅44)
between the two dissection types.
The overall pelvic positivity rate was 9⋅3 per cent in this
study. In contrast, pelvic positivity rates of approximately
30 per cent have been reported in patients with palpable
disease15,31. However, even in these patients the extent of
surgery does not seem to affect outcome15. Many patients,
both those with a positive SNB and those with palpable
disease, who undergo ilioinguinal dissection are therefore
exposed to a potentially higher risk of morbidity but may
not benefit from any therapeutic effect.
One limitation that must be considered when interpret-
ing the present results is the retrospective study design,
which is subject to numerous biases. Another is selection
bias. The decision to deviate from routine practice differed
by centre. Patients undergoing ilioinguinal dissection in
centres where this was not standard practice presumably
had an unfavourable preoperative prognosis. The potential
therapeutic benefit of ilioinguinal dissection could there-
fore be partly counterbalanced by unfavourable prognostic
factors. However, even in patients with a positive CLND
result, recurrence patterns and estimated 5-yearMSS, DFS
and DMFS did not differ between the two dissection types.
This indicates that the extent of CLND does not influ-
ence recurrence and survival positively or negatively. Other
selection and treatment-based factors may also have played
a considerable role, such as variation in local population,
proportion of patients who underwent SNB, SN positiv-
ity rate per centre, the extent to which radical surgery was
performed, the pathology protocol used, and the extent
to which pathologists searched for nodes. Unfortunately,
details of complications were not available for all patients
in the present series, so this aspect could not be evaluated.
The timing of CLND after diagnosis of melanoma was not
assessed in this study, but it has been demonstrated recently
that this does not seem to influence tumour load, DFS or
MSS32.
To date, the therapeutic value of CLND in patients with
a positive SNB has not yet been proven in prospective
randomized trials33,34. The DeCOG-SLTmulticentre trial
randomized patients with a positive SNB to undergo axil-
lary or inguinal CLND, or observation. The trial showed
no difference in DMFS, overall survival or DFS, not even a
trend towards better survival for the CLND group. How-
ever, it was underpowered, and was criticized for having
a majority of patients with a relatively low SN tumour
load34. A more definitive answer to this controversial
and long-standing question will be provided by MSLT-II,
which has included a larger number of patients with long
follow-up4. The EAGLE FM trial35 is focusing on the
question of whether to perform inguinal or ilioinguinal
dissection in patients with groin metastases; patients with
a positive SNB or palpable nodal metastases in the groin
will be randomized to inguinal or ilioinguinal dissection.
However, if MSLT-II does not show a survival benefit for
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CLND, it will be less important to know whether to per-
form an inguinal or ilioinguinal dissection.
Despite these forthcoming developments, there remains
a role for CLND in the near future. Currently all adju-
vant therapy trials require complete pathological nodal
staging of patients with stage III disease (by lymph node
dissection) before inclusion. Eggermont and colleagues36
reported that 10mg/kg ipilimumab resulted in a significant
increase of 11 per cent in recurrence-free and overall sur-
vival compared with placebo. The mortality risk was 28 per
cent lower with ipilimumab than with placebo, and the risk
of DMFS was 24 per cent higher. Although more research
is necessary before ipilimumab can be implemented safely
as standard adjuvant therapy, these results seem promis-
ing. Ongoing trials with other agents may also report a
survival benefit in the next few years, all based on adju-
vant therapy after lymph node dissection. Thus, CLND
will remain a standard procedure for a while, either as a cri-
terion for entry into trials or, for example, as a prerequisite
for Food and Drug Administration/European Medicines
Agency-approved adjuvant therapy.
The present study found no significant difference in
recurrence pattern and survival rates between patients
undergoing either inguinal or ilioinguinal dissection for a
positive SNB, even in the subgroup with a positive CLND
result. The risk of pelvic nodal involvement was low (9⋅3
per cent). Therefore, inguinal dissection seems a safe first
approach to CLND in patients with a positive SNB.
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